Insider Trading Alert - INFN, OHI And SNA Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, July 30, 2014, 50 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $282.88 to $148,399,440.00.

Highlighted Stocks Traded by Insiders:

Infinera (INFN) - FREE Research Report

Wegleitner Mark A, who is Director at Infinera, sold 4,500 shares at $9.12 on July 30, 2014. Following this transaction, the Director owned 29,467 shares meaning that the stake was reduced by 13.25% with the 4,500-share transaction.

The shares most recently traded at $9.19, up $0.07, or 0.77% since the insider transaction. Historical insider transactions for Infinera go as follows:

  • 4-Week # shares bought: 25,000
  • 4-Week # shares sold: 25,000
  • 12-Week # shares bought: 25,000
  • 12-Week # shares sold: 25,000
  • 24-Week # shares bought: 25,000
  • 24-Week # shares sold: 55,000

The average volume for Infinera has been 1.6 million shares per day over the past 30 days. Infinera has a market cap of $1.1 billion and is part of the technology sector and telecommunications industry. Shares are down 5.52% year-to-date as of the close of trading on Wednesday.

Infinera Corporation provides optical transport networking (OTN) equipment, software, and services to communications service providers, Internet content providers, cable operators, and subsea network operators worldwide. Currently, there are 5 analysts who rate Infinera a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on INFN - FREE

TheStreet Quant Ratings rates Infinera as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and impressive record of earnings per share growth. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and a generally disappointing performance in the stock itself. Get the full Infinera Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Omega Healthcare Investors (OHI) - FREE Research Report

Pickett C Taylor, who is Chief Executive Officer at Omega Healthcare Investors, sold 10,800 shares at $39.05 on July 30, 2014. Following this transaction, the Chief Executive Officer owned 232,049 shares meaning that the stake was reduced by 4.45% with the 10,800-share transaction.

The shares most recently traded at $36.85, down $2.20, or 5.96% since the insider transaction. Historical insider transactions for Omega Healthcare Investors go as follows:

  • 4-Week # shares bought: 32,424
  • 4-Week # shares sold: 20,000
  • 12-Week # shares bought: 32,424
  • 12-Week # shares sold: 147,500
  • 24-Week # shares bought: 32,424
  • 24-Week # shares sold: 172,500

The average volume for Omega Healthcare Investors has been 995,900 shares per day over the past 30 days. Omega Healthcare Investors has a market cap of $4.7 billion and is part of the financial sector and real estate industry. Shares are up 24.4% year-to-date as of the close of trading on Wednesday.

Omega Healthcare Investors, Inc. is a real estate investment firm. The firm invests in the real estate markets of United States. It invests in healthcare facilities, primarily in long-term healthcare facilities in order to create its portfolio. Omega Healthcare Investors, Inc. The stock currently has a dividend yield of 5.51%. The company has a P/E ratio of 24.5. Currently, there is 1 analyst who rates Omega Healthcare Investors a buy, 2 analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OHI - FREE

TheStreet Quant Ratings rates Omega Healthcare Investors as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins, notable return on equity and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Omega Healthcare Investors Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Snap-on (SNA) - FREE Research Report

Moreno Jeanne M, who is VP & Chief Information Officer at Snap-on, sold 1,144 shares at $125.01 on July 30, 2014. Following this transaction, the VP & Chief Information Officer owned 10,933 shares meaning that the stake was reduced by 9.47% with the 1,144-share transaction.

The shares most recently traded at $121.63, down $3.38, or 2.78% since the insider transaction. Historical insider transactions for Snap-on go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 950
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 950
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 14,623

The average volume for Snap-on has been 298,500 shares per day over the past 30 days. Snap-on has a market cap of $7.2 billion and is part of the industrial goods sector and industrial industry. Shares are up 12.34% year-to-date as of the close of trading on Wednesday.

Snap-on Incorporated manufactures and markets tools, equipment, diagnostics, and repair information and systems solutions for professional users worldwide. The stock currently has a dividend yield of 1.42%. The company has a P/E ratio of 19.2. Currently, there are 3 analysts who rate Snap-on a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on SNA - FREE

TheStreet Quant Ratings rates Snap-on as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Snap-on Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Jim Cramer: Oil Needs to Go Down to See Worldwide Growth Pick Up

Jim Cramer: Oil Needs to Go Down to See Worldwide Growth Pick Up

Jim Cramer on the Problem With the Case for More Rate Hikes

Jim Cramer on the Problem With the Case for More Rate Hikes

Video: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

Video: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

'Strong Case for More Rate Hikes,' Says Fed Chair Jerome Powell

'Strong Case for More Rate Hikes,' Says Fed Chair Jerome Powell

Fed Chief Uncertain About Policy-Making as Unemployment Hits 18-Year Low

Fed Chief Uncertain About Policy-Making as Unemployment Hits 18-Year Low